Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 6/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.39 |
| ▸ | NPY1R | P25929 | 4/20 | 0.39 |
| ▸ | NPY2R | P49146 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19445744 | 1.00 | HDAC3 (0.40) | HDAC3HDAC4HDAC1EGFRHDAC7 | |
| SCHEMBL10263117 | 0.95 | HDAC1 (0.42) | HDAC3HDAC4HDAC1EGFRHDAC7 | |
| SCHEMBL19445629 | 0.95 | NPY4R (0.37) | HDAC3HDAC4HDAC1EGFRHDAC7 | |
| SCHEMBL10262456 | 0.93 | NPY4R (0.45) | HDAC3HDAC4HDAC1EGFRHDAC7 | |
| SCHEMBL10260131 | 0.93 | NPY4R (0.43) | HDAC3HDAC4HDAC1EGFRHDAC7 | |
| SCHEMBL19445529 | 0.92 | NPY4R (0.42) | HDAC3HDAC4HDAC1EGFRHDAC7 | |
| SCHEMBL18116730 | 0.90 | NPY4R (0.41) | NPY4RNPY5RNPY1RNPY2RTERT | |
| SCHEMBL10260136 | 0.90 | NPY4R (0.41) | NPY4RNPY5RNPY1RNPY2RMMP2 | |
| SCHEMBL12518297 | 0.90 | NPY4R (0.41) | NPY4RNPY5RNPY1RNPY2RMMP2 | |
| SCHEMBL19214481 | 0.90 | NPY4R (0.41) | NPY4RNPY5RNPY1RNPY2RMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10206894-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9457027-B2 | Compounds for use in treatment of mucostis | CELLCEUTIX CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160213668-A1 | Compounds for use in Treatment of Mucostis | INNOVATION PHARMACEUTICALS INC. | 2016-07-28 | — | — | US | disclosed |
| US-9155738-B2 | Compounds for use in treatment of mucostitis | CELLCEUTIX CORPORATION (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140364364-A1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | INNOVATION PHARMACEUTICALS INC. | 2014-12-11 | — | — | US | disclosed |
| US-8802683-B2 | Compounds for use in treatment of mucositis | CELLCEUTIX CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120258141-A9 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110178104-A1 | Anti-Heparin Compounds | POLYMEDIX INC. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, MMP8 | HDAC3 328/4885HDAC4 454/4885HDAC1 562/4885 |
| US-20140364364-A1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | MUC1, FUT6, MMP8 | HDAC3 328/4885HDAC4 454/4885HDAC1 562/4885 |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | HDAC3 328/4885HDAC4 454/4885HDAC1 562/4885 |
| US-20120258141-A9 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | HDAC3 303/4885HDAC4 684/4885HDAC1 999/4885 |
| US-20120039945-A1 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | HDAC3 303/4885HDAC4 684/4885HDAC1 999/4885 |
| US-10206894-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, SI | HDAC3 291/4885HDAC4 453/4885HDAC1 405/4885 |
| US-20110178104-A1 | Anti-Heparin Compounds | SERPINC1, CFH, SERPINH1 | HDAC3 41/4885HDAC4 141/4885HDAC1 72/4885 |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | HDAC3 328/4885HDAC4 454/4885HDAC1 562/4885 |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | MUC1, FUT6, SI | HDAC3 291/4885HDAC4 453/4885HDAC1 405/4885 |
| US-20160213668-A1 | Compounds for use in Treatment of Mucostis | MUC1, SOST, ALG1 | HDAC3 912/4885HDAC4 921/4885HDAC1 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.